Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial

Genmab shares rose more than 6% after interim late-stage data for Epkinly + lenalidomide in 2L diffuse large B-cell lymphoma showed a PFS hazard ratio (HR) of 0.40 vs R-GemOx, with both results statistically significant. Bank of America said the outcome rebuts concerns from the prior 2L monotherapy PIII miss and expects the larger first-line trial interim readout around mid-2026, citing an HR <0.65 as the success bar. The positive data could improve sentiment into a busier H2 with additional readouts (Rina-S and Petosemtamab), with potential for up to ~40% upside to the firm’s 2035 EPS estimate.

Analysis

This is better read as a de-risking event for GMAB’s pipeline narrative than as a material near-term earnings inflection. The main market mechanism is not the 2L revenue pool itself; it is the increase in confidence that GMAB can convert its subcutaneous/oral administration advantage into a cleaner commercial franchise than IV competitors, which supports a higher probability-weighted value on the broader hematology platform.

The second-order effect is on relative positioning versus Roche/RHHBY and other lymphoma developers: if physicians perceive similar efficacy with easier administration, share can shift faster than the headline peak-sales math implies, particularly in community oncology where infusion-chair time is a bottleneck. That said, the current move likely underprices the difference between “competitive data” and “registrational/launchable product”; reimbursement, sequencing, and patient-selection dynamics will decide whether this becomes a durable share-gain story over 6-18 months.

The bigger catalyst path is the first-line readout and the two wholly owned oncology assets later this year. A successful first-line interim would matter far more for valuation than the 2L data, because it can re-rate GMAB from a single-asset story into a multi-shot platform with meaningful EPS optionality. Contrarian risk: the market may be extrapolating too aggressively from a favorable interim signal, while the actual falsifier is any sub-0.5x win probability slipping on first-line timing, safety, or durability versus chemo/immunotherapy alternatives.

Key Decisions for Investors

• Long GMAB into the first-line interim window with a 1-3 month horizon; use common or a 3-6 month call spread to participate in upside while defining event risk. Falsifier: if the stock fails to hold post-data gains and trades back below the pre-announcement breakout level, the de-risking thesis is weakening.
• Pair trade: long GMAB / short RHHBY on a 1-3 month horizon if you want to express the commercial-convenience advantage rather than biotech beta. This works best if oncology sentiment improves but Roche-specific pipeline visibility remains muted.
• Avoid overpaying for momentum: if GMAB rerates another 8-12% before first-line data, consider scaling with a staged entry or using a call spread rather than outright stock. The near-term 2L revenue contribution is too small to justify a full multiple re-rate by itself.
• Set a catalyst watch on the first-line hazard ratio and safety profile; if interim efficacy does not clear a clearly better-than-competitive bar, trim. The structural thesis is intact only if GMAB can show repeatable wins across multiple assets, not just one salvage-line setting.